Cellectis (CLLS) announces that the Arbitral Tribunal has issued its decision in the arbitration proceedings against Les Laboratoires Servier and Institut de Recherches Internationales Servier IRIS SARL, relating to the License, Development and Commercialization Agreement entered into between Servier and Cellectis on March 6, 2019, as amended. The Tribunal ruled on a partial termination of the License Agreement with respect to product UCART19 V1 (also referred to as “ALLO-501” by Allogene) and provided that Cellectis shall, at Allogene’s request, engage in good-faith discussions regarding the granting of a direct license to product UCART19 V1. All other claims brought by the parties were dismissed.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CLLS:
- Cellectis Unveils Promising Phase 1 Results for Eti-cel at ASH 2025
- Cellectis S.A. Updates Patent License Agreement with University of Minnesota
- Cellectis Unveils Breakthrough in Non-Viral Gene Editing with CssDNA
- Cautious Hold Rating for Cellectis SA Amid Key Clinical and Financial Milestones
- Cellectis S.A. Releases Interim Financial Report for Nine-Month Period Ending September 2025